Breaking News Instant updates and real-time market news.

2019-03-25 16:20:40 VCYT Veracyte $25.73 1.26 (5.15%) 16:20 03/25/19 03/25 16:20 03/25/19 16:20	Veracyte presents new Afirma Xpression Atlas data on MTC at ENDO Veracyte announced that new data from the Afirma Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers, or MTC, are associated with variants from three genes. The findings shed new light on the genomic underpinning of this rare, but aggressive, form of thyroid cancer and were presented at ENDO, the Endocrine Society's annual meeting. For the study, researchers evaluated 77 preoperative fine needle aspiration biopsies from thyroid nodules that were positive for MTC based on Afirma testing and which spanned a range of Bethesda System cytology classification categories. All cases were subsequently evaluated with the Xpression Atlas, which uses RNA whole-transcriptome sequencing to detect 761 variants and 130 fusions in 511 genes that are associated with thyroid cancer. The scientists found that among the MTC cases, 55.8% harbored a RET variant, 9.1% included a KRAS variant, 7.8% contained an HRAS variant, while 2.6% of cases possessed fusions and 26% included no gene variants or fusions.	11 Apr
VCYT Veracyte $25.73 1.26 (5.15%) 07/24/18 PIPR 07/24/18 NO CHANGE Target $11 PIPR Neutral Veracyte price target raised to $11 from $7 at Piper Jaffray Piper Jaffray analyst William Quirk raised his price target for Veracyte to $11 following the company's Q2 sales beat and increased 2018 guidance. Veracyte is entering a "new multi-faceted growth cycle" and deserves a premium multiple, Quirk tells investors in a post-earnings research note. The analyst keeps a Neutral rating on the shares but has a "positive bias." He views the new guidance as "not only achievable but potentially beatable." 10/31/18 JANY 10/31/18 UPGRADE JANY Buy Veracyte upgraded to Buy from Neutral at Janney Montgomery Scott 01/04/19 BTIG 01/04/19 NO CHANGE Target $17 BTIG Buy Veracyte price target raised to $17 from $15 at BTIG BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone. 01/29/19 LSCM 01/29/19 NO CHANGE Target $7 LSCM Buy OncoCyte price target raised to $7 from $4 at Lake Street Lake Street analyst Thomas Flaten said OncoCyte's (OCX) R&D Validation study results are in line with previously published data and better than requirements for commercialization. He noted that a company-sponsored survey of 250 chest physicians previously indicated they would require minimum sensitivity and specificity of 85% and 35%, respectively. Flaten believes the fact that the study results were generated solely on biomarkers creates a favorable competitive advantage relative to competitors Veracyte (VCYT) and BioDesix, he added. Stating that he thinks today's results provide strong evidence the company can move forward with a commercially viable product, Flaten raised his price target to $7 from $4 and keeps a Buy rating on OncoCyte shares.

2019-03-25 16:20:40

VCYT

Veracyte

$25.73: 1.26 (5.15%)

16:20

03/25/19

03/25

16:20

03/25/19

16:20

Veracyte presents new Afirma Xpression Atlas data on MTC at ENDO

Veracyte announced that new data from the Afirma Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers, or MTC, are associated with variants from three genes. The findings shed new light on the genomic underpinning of this rare, but aggressive, form of thyroid cancer and were presented at ENDO, the Endocrine Society's annual meeting. For the study, researchers evaluated 77 preoperative fine needle aspiration biopsies from thyroid nodules that were positive for MTC based on Afirma testing and which spanned a range of Bethesda System cytology classification categories. All cases were subsequently evaluated with the Xpression Atlas, which uses RNA whole-transcriptome sequencing to detect 761 variants and 130 fusions in 511 genes that are associated with thyroid cancer. The scientists found that among the MTC cases, 55.8% harbored a RET variant, 9.1% included a KRAS variant, 7.8% contained an HRAS variant, while 2.6% of cases possessed fusions and 26% included no gene variants or fusions.

11
Apr

VCYT Veracyte

$25.73: 1.26 (5.15%)

07/24/18: PIPR

10/31/18: JANY

01/04/19: BTIG

01/29/19: LSCM

TODAY'S FREE FLY STORIES

SPPI Spectrum $9.83 (0.00%) 10:35 12/09/19 12/09 10:35 12/09/19 10:35 Options	Spectrum put volume heavy and directionally bearish » Bearish flow noted in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
CTIC CTI BioPharma $0.95 (0.00%) 10:33 12/09/19 12/09 10:33 12/09/19 10:33 Hot Stocks	CTI BioPharma: PAC203 results show pactritinib 200mg 'well tolerated' » CTI BioPharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
10:25 12/09/19 12/09 10:25 12/09/19 10:25 General news	Concerns over a year-end spike in the money markets » Concerns over a year-end… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial
10:25 12/09/19 12/09 10:25 12/09/19 10:25 Conference/Events	JPMorgan Mexican strategist to hold an analyst/industry conference call » Mexican Equity Strategist… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial
10:25 12/09/19 12/09 10:25 12/09/19 10:25 Conference/Events	UBS alternative energy windham to hold an analyst/industry conference call » Alternative Energy &… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial

ZG Zillow $40.54 -0.18 (-0.44%) , SPCE Virgin Galactic $8.20 0.92 (12.64%) … 10:20 12/09/19 12/09 10:20 12/09/19 10:20 Initiation	Fly Intel: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (ZG) initiated with a Neutral at Citi. 2. Virgin Galactic (SPCE) initiated with an Overweight at Morgan Stanley. 3. Plains All American (PAA) and Plains GP Holdings (PAGP) initiated with a Neutral at Goldman Sachs. 4. Strata Skin Sciences (SSKN) initiated with a Buy at Ladenburg. 5. Zymeworks (ZYME) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. ZG Zillow $40.54 -0.18 (-0.44%) SPCE Virgin Galactic $8.20 0.92 (12.64%) PAA Plains All American $17.29 -0.01 (-0.06%) PAGP Plains GP Holdings $17.37 0.01 (0.06%) SSKN Strata Skin Sciences $2.20 0.04 (1.85%) ZYME Zymeworks $41.25 -0.45 (-1.08%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Dec 11 Dec 30 Dec 04 Feb
MMM 3M $169.82 -1.675 (-0.98%) , PNC PNC Financial $153.68 -0.13 (-0.08%) … 10:20 12/09/19 12/09 10:20 12/09/19 10:20 Downgrade	Fly Intel: Top five analyst downgrades » Catch up on today's… Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 3M (MMM) downgraded to Neutral from Buy at Citi with analyst Andrew Kaplowitz saying with industrial production having peaked in December 2018, the "industrial cycle" is in the midst of a mild downturn that could stabilize. 2. PNC Financial (PNC) downgraded to Outperform from Top Pick at RBC Capital with analyst Gerard Cassidy saying while the outlook for the stock remains "robust" and he still views the company as one of the top performing U.S. banks, he prefers Truist Financial Corporation as his new Top Pick rated bank stock given the opportunity offered by its recent merger combining BB&T (BBT) and SunTrust (STI). 3. Macy's (M) downgraded to Sell from Neutral at Goldman Sachs with analyst Alexandra Walvis saying while acknowledging the stock's year-to-date underperformance and "already weak sentiment" following the recent deterioration in fundamentals, she sees "significant additional downside" to Macy's retail operations. 4. Chevron (CVX) downgraded to Neutral from Buy at Citi with analyst Alastair Syme saying Chevron has emerged as a "relative safe haven" for energy investors given its balance sheet strength and clear capital allocation; however, the "safe-haven status might now be overplayed." 5. Harvard Bioscience (HBIO) downgraded to Speculative Buy from Buy at Benchmark with analyst Bruce Jackson citing the corporate restructuring that the company is undergoing as part of the new strategic plan introduced in September. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. MMM 3M $169.82 -1.675 (-0.98%) PNC PNC Financial $153.68 -0.13 (-0.08%) M Macy's $14.96 -0.19 (-1.25%) CVX Chevron $117.18 -0.8 (-0.68%) HBIO Harvard Bioscience $2.83 -0.12 (-4.07%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Dec 15 Jan
QRVO Qorvo $109.72 3.04 (2.85%) , SWKS Skyworks $104.55 3.15 (3.11%) … 10:20 12/09/19 12/09 10:20 12/09/19 10:20 Upgrade	Fly Intel: Top five analyst upgrades » Catch up on today's… Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qorvo (QRVO) and Skyworks (SWKS) double upgraded to Buy from Underperform at BofA/Merrill. 2. Fate Therapeutics (FATE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough citing this weekend's update for the company's iPSC-derived NK-cell therapeutics pipeline, initial data for iPSC NKcell therapies FT500 and FT516, and updated comments on CD19 CAR-NK therapeutic FT596. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Katherine Fogertey saying while the shares are up over 30% over the past year, they have lagged the S&P 500 by over 30% since August 22 and now trade at a discount to peers. 4. Huntsman (HUN) and Fortive (FTV) upgraded to Buy from Neutral at Citi. 5. Dow Inc. (DOW) and Kraton (KRA) upgraded to Buy from Hold at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. QRVO Qorvo $109.72 3.04 (2.85%) SWKS Skyworks $104.55 3.15 (3.11%) FATE Fate Therapeutics $19.69 6.05 (44.35%) WING Wingstop $84.26 4.04 (5.04%) HUN Huntsman $23.31 0.48 (2.10%) FTV Fortive $74.68 1.82 (2.50%) DOW Dow Inc. $53.29 0.04 (0.08%) KRA Kraton $23.96 0.92 (3.99%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 12 Dec 13 Dec 18 Dec 19 Dec
TPR Tapestry $25.85 0.305 (1.19%) 10:20 12/09/19 12/09 10:20 12/09/19 10:20 Options	Upside February calls see heavy trading in Tapestry » Upside February calls see… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
SWTX SpringsWorks Therapeutics $28.00 3.01 (12.04%) , GSK GlaxoSmithKline $45.64 0.13 (0.29%) 10:19 12/09/19 12/09 10:19 12/09/19 10:19 Hot Stocks	SpringsWorks reports Glaxo presentation of preclinical data on nirogacestat » SpringWorks Therapeutics… SWTX SpringsWorks Therapeutics $28.00 3.01 (12.04%) GSK GlaxoSmithKline $45.64 0.13 (0.29%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec

$NSD NASDAQ Market Internals $0.00 (0.00%) 10:17 12/09/19 12/09 10:17 12/09/19 10:17 Technical Analysis	NASDAQ market internals summary » Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AGIO Agios Pharmaceuticals $44.49 3.56 (8.70%) 10:16 12/09/19 12/09 10:16 12/09/19 10:16 Hot Stocks	Agios Pharmaceuticals reports new data from DRIVE PK Phase 2 study » Agios Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 13 Dec
$NYE NYSE Market Internals $0.00 (0.00%) 10:16 12/09/19 12/09 10:16 12/09/19 10:16 Technical Analysis	NYSE market internals summary » Volume is average for… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
FTSV Forty Seven $22.25 7.85 (54.51%) 10:15 12/09/19 12/09 10:15 12/09/19 10:15 Hot Stocks	Forty Seven announces preclinical proof-of-concept data for FSI-174 » Forty Seven announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec
NKTR Nektar $22.00 1.55 (7.58%) 10:15 12/09/19 12/09 10:15 12/09/19 10:15 Hot Stocks	Nektar announces presentation of data for NKTR-255 at ASH » Nektar Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	11 Dec

UPS UPS $116.87 -0.67 (-0.57%) 10:15 12/09/19 12/09 10:15 12/09/19 10:15 Hot Stocks	UPS reports expansion of UPS Worldwide Express, Express Plus across 40 countries » UPS announced an… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
CNC Centene $60.30 -0.69 (-1.13%) 10:15 12/09/19 12/09 10:15 12/09/19 10:15 Options	Centene put volume heavy and directionally bearish » Bearish flow noted in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Dec
CNST Constellation Pharmaceuticals $47.50 3.4 (7.71%) 10:14 12/09/19 12/09 10:14 12/09/19 10:14 Hot Stocks	Breaking Hot Stocks news story on Constellation Pharmaceuticals » Constellation… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec
ACHN Achillion $6.19 0.02 (0.32%) 10:14 12/09/19 12/09 10:14 12/09/19 10:14 Hot Stocks	Achillion reports 'positive' data from Phase 2 danicopan, eculizumab study » Achillion Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Dec
ATRA Atara Biotherapeutics $14.24 0.25 (1.79%) 10:12 12/09/19 12/09 10:12 12/09/19 10:12 Hot Stocks	Atara reports updated long-term clinical results from Tab-cel EBV+ PTLD study » Atara Biotherapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

GLOB Globant $102.78 -0.525 (-0.51%) 10:12 12/09/19 12/09 10:12 12/09/19 10:12 Conference/Events	Globant management to meet with JPMorgan » Meeting to be held in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 11 Dec 16 Jan
CNST Constellation Pharmaceuticals $47.50 3.4 (7.71%) 10:12 12/09/19 12/09 10:12 12/09/19 10:12 Hot Stocks	Constellation Pharmaceuticals provides update on MANIFEST clinical trial » Constellation… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec
DTIL Precision BioSciences $18.00 -1.66 (-8.44%) 10:11 12/09/19 12/09 10:11 12/09/19 10:11 Hot Stocks	Breaking Hot Stocks news story on Precision BioSciences » Precision BioSciences Inc… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec
MTEM Molecular Templates $12.23 (0.00%) 10:10 12/09/19 12/09 10:10 12/09/19 10:10 Hot Stocks	Molecular Templates announces presentations of two posters at ASH » Molecular Templates… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
CAR Avis Budget $31.72 0.545 (1.75%) 10:10 12/09/19 12/09 10:10 12/09/19 10:10 Conference/Events	Avis Budget management to meet with JPMorgan » Meetings to be held in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 10 Dec

Events

Earnings calls, analyst events, roadshows and more

ATEA
Today at 11:00

ASTEA INTERNATIONAL INC. Firm Sponsored Meetings

240 Gibraltar Road, Horsham, PA
BKJ
Today at 11:00

Bancorp Of New Jersey, Inc. Firm Sponsored Meetings

2117 Route 4 East, Fort Lee, NJ
Today at 11:00

Economics & Strategy--Mexico Industry Meetings
Today at 11:00

Alternative Energy & Environmental Services Industry Meetings
Today at 11:00

Biotechnology Industry Meetings
Today at 11:30

3-Month Bill Auction Government Event
Today at 11:30

6-Month Bill Auction Government Event
SPT
Today at 12:00

Sprout Social - SPT Syndicate Roadshows

San Francisco, CA
APRE
Today at 12:00

Aprea Therapeutics Firm Sponsored Meetings

Hyatt Regency Orlando, Orlando, FL
CHMA
Today at 12:00

Biotechnology Industry Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	CRWD X CRWD Crowdstrike Block Trade Managers: Goldman Sachs $48.95-50.89 2.2M Shares AUPH X AUPH Aurinia Pharmaceuticals Secondary Managers: Jefferies & SVB Leerink, H.C. Wainwright, Oppenheimer, Bloom Burton $15.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	XP X XP XP IPO Managers: Goldman Sachs, JPMorgan, Morgan Stanley, XP & Itau BBA, BofA/Merrill, Citi, Credit Suisse, UBS $22.00-25.00 72.511M Shares
Wed	BILL X BILL Bill.com IPO Managers: Goldman Sachs, BofA/Merrill, Jefferies & KeyBanc, Canaccord, Needham, William Blair $16.00-18.00 8.824M Shares EH X EH Ehang IPO Managers: Morgan Stanley, Needham, Tigress Financial, Prime Number $12.50-14.50 3.2M Shares MNRL X MNRL Brigham Minerals Secondary Managers: Credit Suisse, Goldman Sachs & RBC Capital $19.70 11M Shares
Thurs	OCFT X OCFT OneConnect IPO Managers: Morgan Stanley, Goldman Sachs, JPMorgan & Ping An of China, BofA/Merrill, HSBC, CLSA, KeyBanc $12.00-14.00 36M Shares SPT X SPT Sprout Social IPO Managers: Goldman Sachs, Morgan Stanley, KeyBanc & William Blair, Canaccord, Stifel $16.00-18.00 8.824M Shares
Fri	No deals

View All Syndicate Announcements »

Veracyte presents new Afirma Xpression Atlas data on MTC at ENDO

TODAY'S FREE FLY STORIES

Get Full Fly Access